Mireille Cantarini

13.2k total citations · 8 hit papers
81 papers, 8.1k citations indexed

About

Mireille Cantarini is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Mireille Cantarini has authored 81 papers receiving a total of 8.1k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Pulmonary and Respiratory Medicine, 48 papers in Oncology and 36 papers in Molecular Biology. Recurrent topics in Mireille Cantarini's work include Lung Cancer Treatments and Mutations (61 papers), Colorectal Cancer Treatments and Studies (22 papers) and Cancer Genomics and Diagnostics (17 papers). Mireille Cantarini is often cited by papers focused on Lung Cancer Treatments and Mutations (61 papers), Colorectal Cancer Treatments and Studies (22 papers) and Cancer Genomics and Diagnostics (17 papers). Mireille Cantarini collaborates with scholars based in United Kingdom, United States and South Korea. Mireille Cantarini's co-authors include Pasi A. Jänne, James Chih‐Hsin Yang, Kenneth S. Thress, J. Carl Barrett, Enriqueta Felip, Geoffrey R. Oxnard, Myung‐Ju Ahn, Cloud P. Paweletz, Suresh S. Ramalingam and Paul Frewer and has published in prestigious journals such as New England Journal of Medicine, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Mireille Cantarini

80 papers receiving 8.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

2015 1.6k citations Pasi A. Jänne, James Chih‐Hsin Yang et al. profile →
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

2015 1.2k citations Kenneth S. Thress, Cloud P. Paweletz et al. profile →
Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer

2016 641 citations Geoffrey R. Oxnard, Kenneth S. Thress et al. profile →
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity

2016 523 citations Peter Ballard, James Yates et al. Clinical Cancer Research profile →
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study

2016 502 citations Glenwood Goss, Chun‐Ming Tsai et al. profile →
EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291

2015 401 citations Kenneth S. Thress, Simon Dearden et al. profile →
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study

2020 295 citations Lecia V. Sequist, Ji‐Youn Han et al. profile →
Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET -Amplified Non–Small Cell Lung Cancer: TATTON

2022 95 citations Ryan J. Hartmaier, Aleksandra Markovets et al. Cancer Discovery profile →

Peers

Mireille Cantarini

PRM

ONCOL

PFM

Daniel B. Costa United States

Sean Tracy United States

Sara M. Haserlat United States

Juliann Chmielecki United States

Andrea Kay United States

Helena A. Yu United States

Caicun Zhou China

Takayuki Kosaka Japan

Patricia L. Harris United States

Haiyi Jiang Japan

Daniel B. Costa United States

Mireille Cantarini

8.4k ×1.4

PRM

6.8k ×1.3

ONCOL

3.6k ×1.1

2.2k ×0.9

712 ×1.2

PFM

Citations per year, relative to Mireille Cantarini Mireille Cantarini (= 1×) peers Daniel B. Costa

Countries citing papers authored by Mireille Cantarini

Since Specialization

Citations

This map shows the geographic impact of Mireille Cantarini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mireille Cantarini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mireille Cantarini more than expected).

Fields of papers citing papers by Mireille Cantarini

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mireille Cantarini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mireille Cantarini. The network helps show where Mireille Cantarini may publish in the future.

Co-authorship network of co-authors of Mireille Cantarini

This figure shows the co-authorship network connecting the top 25 collaborators of Mireille Cantarini. A scholar is included among the top collaborators of Mireille Cantarini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mireille Cantarini. Mireille Cantarini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hartmaier, Ryan J., Aleksandra Markovets, Myung‐Ju Ahn, et al.. (2022). Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET -Amplified Non–Small Cell Lung Cancer: TATTON. Cancer Discovery. 13(1). 98–113. 95 indexed citations breakdown →

Yang, James Chih‐Hsin, Yuichiro Ohe, Chao‐Hua Chiu, et al.. (2022). Osimertinib plus Selumetinib in EGFR -Mutated Non–Small Cell Lung Cancer After Progression on EGFR-TKIs: A Phase Ib, Open-Label, Multicenter Trial (TATTON Part B). Clinical Cancer Research. 28(19). 4222–4231. 10 indexed citations

Ahn, Myung‐Ju, Byoung Chul Cho, Xiaoling Ou, et al.. (2022). Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter Trial. Journal of Thoracic Oncology. 17(5). 718–723. 50 indexed citations

Jenkins, Suzanne, James Chih‐Hsin Yang, Suresh S. Ramalingam, et al.. (2017). Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non–Small Cell Lung Cancer. Journal of Thoracic Oncology. 12(7). 1061–1070. 221 indexed citations

Zhou, C.Z., Ying Cheng, Y. Chen, et al.. (2017). Osimertinib in Asia-Pacific patients (pts) with EGFR T790M-positive advanced NSCLC: Updated Phase II study results including progression-free survival (PFS). Annals of Oncology. 28. v484–v484. 2 indexed citations

Jenkins, Suzanne, James Chih‐Hsin Yang, Pasi A. Jänne, et al.. (2017). EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib. Journal of Thoracic Oncology. 12(8). 1247–1256. 46 indexed citations

Thress, Kenneth S., Vivien N. Jacobs, Helen K. Angell, et al.. (2017). Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial. Journal of Thoracic Oncology. 12(10). 1588–1594. 17 indexed citations

Goss, Glenwood, Chun‐Ming Tsai, Frances A. Shepherd, et al.. (2017). MA16.11 CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC: Pooled Data from Two Phase II Trials. Journal of Thoracic Oncology. 12(1). S440–S441. 23 indexed citations

Ballard, Peter, James Yates, Zhenfan Yang, et al.. (2016). Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity. Clinical Cancer Research. 22(20). 5130–5140. 523 indexed citations breakdown →

10.

Oxnard, Geoffrey R., Kenneth S. Thress, Ryan S. Alden, et al.. (2016). 135O_PR: Plasma genotyping for predicting benefit from osimertinib in patients (pts) with advanced NSCLC. Journal of Thoracic Oncology. 11(4). S154–S154. 11 indexed citations

11.

Thress, Kenneth S., Joseph Geradts, Martin Schüler, et al.. (2015). Design, execution, and preliminary biomarker results from paired tumor biopsy cohorts of the AZD9291 AURA trial. Journal of Thoracic Oncology. 1 indexed citations

12.

Jänne, Pasi A., Myung‐Ju Ahn, D.-W. Kim, et al.. (2015). A Phase I Study of AZD9291 in Patients with Egfr-Tki-Resistant Advanced Nsclc – Updated Progression Free Survival and Duration of Response Data. Annals of Oncology. 26. i57–i57. 15 indexed citations

13.

Kirkwood, John M., Lars Bastholt, Caroline Robert, et al.. (2011). Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma. Clinical Cancer Research. 18(2). 555–567. 218 indexed citations

14.

Horák, Jiří, Jeff White, Adrian L. Harris, et al.. (2011). The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib. Cancer Chemotherapy and Pharmacology. 68(6). 1485–1495. 25 indexed citations

15.

Banerji, Udai, D. Ross Camidge, Henk M.W. Verheul, et al.. (2010). The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer. Clinical Cancer Research. 16(5). 1613–1623. 176 indexed citations

16.

Ellison, Gillian, Emma Donald, Gael McWalter, et al.. (2010). A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples. Journal of Experimental & Clinical Cancer Research. 29(1). 132–132. 132 indexed citations

17.

Desar, Ingrid M.E., H. Jorn Bovenschen, Mireille Cantarini, et al.. (2010). Case studies showing clinical signs and management of cutaneous toxicity of the MEK1/2 inhibitor AZD6244 (ARRY-142886) in patients with solid tumours. Acta Oncologica. 49(1). 113–116. 14 indexed citations

18.

Board, Ruth, Gillian Ellison, Maria Orr, et al.. (2009). Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study. British Journal of Cancer. 101(10). 1724–1730. 78 indexed citations

19.

Wilson, Clive, Bridget O’Mahony, Mireille Cantarini, et al.. (2009). Do gastrointestinal transit parameters influence the pharmacokinetics of gefitinib?. International Journal of Pharmaceutics. 376(1-2). 7–12. 23 indexed citations

20.

Cooper, Kevin D., Paul Martin, Aaron Dane, et al.. (2002). The effect of fluconazole on the pharmacokinetics of rosuvastatin. European Journal of Clinical Pharmacology. 58(8). 527–531. 92 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact